Article info

Download PDFPDF
Extended report
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
  1. Correspondence to Dr G J Wolbink, Department of Rheumatology, Jan van Breemen Institute, Dr Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands; g.wolbink{at}janvanbreemen.nl
View Full Text

Citation

Jamnitski A, Bartelds GM, Nurmohamed MT, et al
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

Publication history

  • Accepted August 10, 2010
  • First published November 10, 2010.
Online issue publication 
January 13, 2011

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.